Dr. Rettig on the Evolving Use of Triplet Regimens in mHSPC
March 10th 2023Matthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.
Read More